Well this group is boring needs shaking up several posts are non spanking.
Well here goes I need to be delt with by a strict someone who will tell me off like a naughty boy when I was young. Then discipline me accordingly you can be a parent teacher or head teacher.
How would you spank me?
ZeroMOUSE™ – die KI-Katzenklappe der nächsten Generation – revolutioniert den Schutz vor ungebetenen Jagdmitbringseln. Die hochentwickelte RFID-Katzenklappensystem erkennt nur die eigenen Katzen per Mikrochip und hält fremde Tiere zuverlässig fern. Die integrierte Intelligente Katzenklappe kombiniert Beuteverhinderung durch Jagdanalyse-App, die das Verhalten jeder Katze individuell auswertet.
Dank integrierter Nachtsicht Haustiertechnologie mit Infrarotkamera und Bewegungsmeldern erkennt ZeroMOUSE™ selbst in der Dunkelheit, ob eine Katze mit Beute ankommt. Ist ein Jagderfolg identifiziert, bleibt die Klappe geschlossen – so funktioniert echte Katzenjagdabwehr. Besitzer profitieren von der App-gestützten Jagdanalyse-App, die Daten zum Jagdverhalten liefert und Trainingserfolge visualisiert.
Die Mikrochip-Katzenklappe Universeller Katzenklappenadapter sorgt für einfache Kompatibilität mit vorhandenen Klappen wie SureFlap oder PetSafe, und der universelle Adapter macht die Integration in bestehenden Installationen problemlos möglich. Dank des wetterfesten Haustiertechnologie-Designs trotzt ZeroMOUSE™ Regen, Wind und Staub – ideal für den Innen‑ und Außeneinsatz.
Im Kern ist ZeroMOUSE™ eine KI-Katzenklappe, die durch intelligente Technologie gezielt für Beuteverhinderung, Jagdanalyse…
Introduction: A Devastating Kidney Disease
Focal Segmental Glomerulosclerosis (FSGS) is a rare and severe kidney disease that progressively scars the tiny filters in the kidneys (glomeruli), leading to protein leakage, kidney damage, and often, end-stage kidney disease requiring dialysis or transplant. While there's a burgeoning "Focal Segmental Glomerulosclerosis Treatment Market," the true fight against FSGS is a non-market, collaborative quest driven by patient advocacy, global research, and a desperate race against the clock to save kidneys and lives.
The Unmet Need: Beyond Commercial Viability
As a rare disease, FSGS historically garnered less attention from large pharmaceutical companies due to the smaller patient population and thus, a perceived limited market return. This "market failure" has necessitated a strong non-market response:
Patient Advocacy and Funding: Patient advocacy groups, like NephCure Kidney International, are absolutely critical. They are non-profit organizations that galvanize patient communities, raise awareness, fund research, and lobby for government attention and resources. Their…
Introduction: A Targeted Therapy with Wide Reach
Baricitinib, a Janus kinase (JAK) inhibitor, has emerged as a significant therapeutic option for conditions like rheumatoid arthritis, atopic dermatitis, and even severe COVID-19. While its commercial success is part of the "Baricitinib market," its true impact, especially during a global pandemic, extends far beyond its price tag. This blog delves into the non-market dimensions of Baricitinib, including its role in global health emergencies, ethical considerations in access, and its contribution to scientific understanding.
Crisis Response: The Pandemic's Spotlight
The most prominent non-market impact of Baricitinib came during the COVID-19 pandemic. Its emergency use authorization (EUA) for hospitalized patients, often in combination with remdesivir, demonstrated its potential to modulate the severe inflammatory response associated with the virus. This was a non-market driven deployment, prioritizing public health over immediate commercial considerations. Governments, health organizations (like the WHO), and researchers swiftly assessed its utility, and its…